Archer Aviation vs. Rocket Lab: Which Aerospace Stock Is a Better Buy in 2026?

Rocket Lab is favored over Archer Aviation based on its more established revenue base, with FY2025 revenue of $601.8 million, up 38%, versus Archer's roughly $300,000, and a smaller net loss of $198.2 million versus Archer's $618.2 million loss. Rocket Lab's backlog exceeded $2 billion in 2026 and its pending Iridium acquisition and Neutron program could expand its addressable market, although its 1,100x forward P/E signals an elevated valuation. Archer retains upside from FAA certification progress, a conditional United order worth up to $1.5 billion, and Stellantis/Boeing partnerships, but it remains pre-commercial, generated negative $511.7 million of free cash flow, and faces substantial certification and manufacturing-scale risk.

Analysis

The article contains material claims that require verification before any capital is deployed, particularly the purported RKLB-IRDM transaction and ACHR acquisition of Boeing assets. If either claim is unverified, the comparison is built on false catalysts and is not investable; this is especially important because both equities trade on long-duration execution narratives, where incremental valuation support is highly sensitive to backlog quality, financing needs, and certification/launch milestones rather than current earnings.

RKLB is structurally the higher-quality operating platform because its space-systems business can smooth launch cadence volatility and monetize government demand beyond a single vehicle. The key equity inflection over the next 6-18 months is not revenue growth alone but whether Neutron reaches credible schedule and cost milestones without materially increasing cash burn; a delay would compress the premium assigned to a future medium-lift franchise and could benefit established alternatives including NOC and privately held launch competitors.

ACHR and JOBY should be treated as regulatory-duration assets, not transportation companies. A certification advance can produce a sharp days-to-weeks repricing, but the 1-3 year bottleneck is production certification, fleet financing, pilot/maintenance infrastructure, and unit economics; OEM affiliation reduces perceived funding risk but does not establish repeatable aircraft margins. ACHR's conditional airline demand should therefore receive a substantial probability haircut until binding deposits, delivery schedules, and customer-funded infrastructure commitments are disclosed.

Contrarianly, the market may over-credit RKLB's commercialization narrative if it treats backlog as near-term, high-margin revenue and underestimates fixed-cost absorption from Neutron development. Conversely, ACHR's low current revenue is obvious; the less-priced upside would be a capital-light manufacturing and service model that shifts certification risk into a rapid order-conversion event, though that remains an alert rather than a base-case trade.

Key Decisions for Investors

• No event-driven position on the alleged RKLB/IRDM deal until definitive merger documents, consideration, financing, and regulatory timetable are independently verified. If confirmed as cash-heavy or equity-financed, reassess RKLB dilution and IRDM spread; if unconfirmed, treat related price moves as fade candidates rather than fundamental rerating.
• Maintain a modest long RKLB / short NOC relative-value watch position only after confirming Neutron schedule milestones and quarterly space-systems gross-margin progression. Target a 6-12 month horizon; exit if Neutron timing slips by more than one quarter, annualized FCF burn accelerates, or space-systems margin declines despite revenue growth.
• Avoid outright ACHR exposure ahead of certification updates; use ACHR versus JOBY only as a catalyst trade when one issuer demonstrates a verifiable certification or production milestone advantage. Limit risk through a 1-3 month options structure because a sector-wide FAA delay would likely correlate both names lower.
• Monitor BA and STLA disclosures for binding capital commitments, supplier guarantees, or production-capacity obligations related to ACHR. Such commitments would be more informative than promotional partnership language: firm support would reduce ACHR financing-tail risk, while its absence would reinforce future equity-raise risk.